GHK-Cu cream or an injectable blend: what actually changes?
If your goal is smoother-looking skin or a better-tolerated skincare routine, begin there. A GHK-Cu cream and an injectable blend containing GHK-Cu involve different routes, ingredients and evidence. An injection is not automatically a stronger version of a facial cream, and a higher percentage does not establish a better result.
Compare the actual products, not just the shared ingredient
The catalog includes a GHK-Cu facial cream and a GHK-Cu/epithalon injectable blend. KLOW is another injectable combination containing GHK-Cu with additional peptides. These are distinct preparations. There is no standalone GHK-Cu injection described by this comparison.
For a skin concern, tell your clinician whether you mean texture, irritation, wrinkles or recovery from a recent procedure. Ask what is being proposed for that specific concern. The presence of the same ingredient in several products does not establish that they can be substituted, combined or ranked by strength.
Topical human research has important limits
A clinical study of topical GHK-Cu gel reported better healing in diabetic neuropathic ulcers as part of structured wound care. Participants also received debridement, pressure-relieving footwear and other care. It was not a trial of facial cream for wrinkles, and it did not test injectable GHK-Cu.
A small study after CO2 laser resurfacing had thirteen participants complete follow-up. Objective assessments did not find a between-group advantage in redness, wrinkles or overall skin quality, although a patient questionnaire favored GHK-Cu. That mixed result is more useful than presenting all topical research as proof that copper peptides reliably improve cosmetic outcomes.
Read: Mulder et al. Topical GHK-Cu in diabetic neuropathic ulcers; Miller et al. Topical copper tripeptide after CO2 laser resurfacing.
Adding epithalon creates another evidence question
The GHK-Cu/epithalon product combines two ingredients. Research on either ingredient separately does not establish the performance of the finished mixture. The recent epitalon telomere paper, with a published correction, studied laboratory cell lines; it did not measure longer life, younger-looking skin or the clinical effects of this injectable combination in people.
FDA also describes limited human safety information and potential immune-reaction concerns for injectable GHK-Cu. Those concerns are specific to injectable use and should not be copied word for word onto topical cream as though the routes were identical. They do matter when someone suggests an injection as a routine upgrade from skincare.
Read: Al-Dulaimi et al. Epitalon and telomere length in cell lines; Correction to the epitalon cell-line paper; FDA: Bulk drug substances with potential significant safety risks.
A percentage is useful information, not a results ranking
Knowing the concentration helps identify what has been prescribed. It does not tell you that doubling the percentage doubles the benefit. The human studies discussed here do not establish that one offered compounded cream strength produces better facial results than another.
Bring your full skincare routine, including retinoids, exfoliating products and recent procedures, to the consultation. Ask how the proposed cream would fit, how irritation would be handled and when to review your response. After a procedure, follow the treating clinician’s aftercare directions before introducing another active product. A wound study is not permission to apply a facial prescription to an open wound.
Read: Mulder et al. Topical GHK-Cu in diabetic neuropathic ulcers; Miller et al. Topical copper tripeptide after CO2 laser resurfacing.
Choose a clear goal and a way to judge the response
For a cosmetic skin goal, agree on what you will assess and keep other routine changes visible. Consistent photographs and notes about comfort may help the discussion, but changes over time cannot by themselves prove which product caused them. Decide when an uncertain or irritating treatment should be reconsidered.
Compounded products have not undergone FDA approval. A prescription and a licensed pharmacy do not turn ingredient research into proof for an untested route or blend. The useful next step is a specific conversation about your skin, the exact preparation and whether the expected benefit justifies its uncertainty and burden.
Sources
- Mulder et al. Topical GHK-Cu in diabetic neuropathic ulcers
Wound Repair and Regeneration, 1994. Gel with standardized wound care.
- Miller et al. Topical copper tripeptide after CO2 laser resurfacing
Archives of Facial Plastic Surgery, 2006. Small study with mixed subjective and objective findings.
- Al-Dulaimi et al. Epitalon and telomere length in cell lines
Biogerontology, 2025. Laboratory work, not a trial of human aging or an injectable blend.
- Correction to the epitalon cell-line paper
Biogerontology, 2025. Read with the original laboratory paper.
- FDA: Bulk drug substances with potential significant safety risks
Includes route-specific concerns and withdrawn-nomination listings; not a blanket determination of legal eligibility.
- FDA: Compounding questions and answers
Compounded products do not undergo FDA approval.
